Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...

Operator Good afternoon, and welcome to the Sarepta Therapeutics fourth quarter and full year 2024 financial results ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by stock analysts at HC ...

Q4 2024 Earnings Call Transcript February 26, 2025 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $1 ...

Sarepta Therapeutics Inc (SRPT) reports a 75% increase in quarterly revenues and outlines ambitious growth plans for 2025.

BofA lowered the firm’s price target on Sarepta (SRPT) to $210 from $217 and keeps a Buy rating on the shares. Management is confident in FY25 ...

Morgan Stanley raised the firm’s price target on Sarepta (SRPT) to $196 from $195 and keeps an Overweight rating on the shares. Q4 revenues ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Net product revenues for the fourth quarter 2024 totaled $638.2 million, a 75% increase over the same quarter of the prior year – ELEVIDYS net product revenue for the quarter totaled $384.2 ...

ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...

CAMBRIDGE, Mass. - Sarepta Therapeutics (NASDAQ: SRPT) reported fourth quarter earnings that beat analyst expectations, but the stock fell 4.6% as investors focused on rising expenses.

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.